Related Experiment Video
Updated: Mar 16, 2026

A Facile and Efficient Approach for the Production of Reversible Disulfide Cross-linked Micelles
Published on: December 23, 2016
Polysaccharide-based inflammatory microenvironment-responsive nanocarriers for ulcerative colitis: Advances in
Si-Jie Wu1, Ran Feng1, Ran Meng1
1Engineering Research Center of Bio-process, Ministry of Education, Hefei University of Technology, 193 Tunxi Road, Hefei, Anhui, 230009, PR China; School of Food and Biological Engineering, Hefei University of Technology, 193 Tunxi Road, Hefei, Anhui, 230009, PR China.
None:
The worldwide incidence of ulcerative colitis (UC) continues to rise, presenting a growing public health challenge due to its multifactorial etiology and limited therapeutic options. While current therapeutic regimens can alleviate symptoms, they are plagued by constrained efficacy and significant side effects. Advances in nanotechnology have catalyzed the development of polysaccharide-based inflammatory microenvironment-responsive nanocarriers (PIMRNs), offering novel opportunities for UC management. PIMRNs exhibit excellent bioactivity, biocompatibility, and multifunctional modulation capabilities. Their structural design enables precise targeting and spatiotemporally controlled drug release, which can be specifically triggered by the distinctive inflammatory microenvironment of UC, including elevated reactive oxygen species, dysregulated pH, and enzyme overexpression. This microenvironment-responsive delivery system synergistically enhances therapeutic efficacy while minimizing off-target adverse effects. This review outlines the dynamic inflammatory microenvironment in UC and highlights its pivotal role in guiding the design of PIMRNs. It systematically summarizes recent advances in PIMRNs for UC treatment, articulates fundamental design principles along with optimization strategies to improve their performance, and discusses key challenges and future directions for their clinical translation. Through continued refinement, PIMRNs hold the potential to transform current UC treatment paradigms and enable precision therapy for a range of inflammatory disorders.
More Related Videos
09:11Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model
Published on: February 14, 2021
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
Related Concept Videos
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Modified-Release Drug Delivery Systems: Stimuli-Activated
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids